Compare Marqeta Inc (MQ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs ResMed Inc. — how do they compare? Marqeta Inc trades at $15.91 (market cap $1.63B), while ResMed Inc. trades at $226.99 (market cap $32.78B). The key difference: ResMed Inc. is far larger — about 20.1× Marqeta Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | RMD | |
|---|---|---|
Market Cap | $1.63B | $32.78B |
Sector | Technology | Health |
52-Week High | $26.00 | $293.73 |
52-Week Low | $15.04 | $182.82 |
Enterprise Value | $945.77M | $32.14B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $15.62, up 0.13% with a bearish technical outlook. The company shows improving fundamentals with Q2 2026 revenue growth of 17% and second consecutive GAAP profitability. Recent partnerships with Google and Riskified highlight strategic expansion, while a 4:1 reverse stock split was completed in July 2026. Valuation remains elevated with a P/E of 173, though analyst consensus targets $19.00 with 32% buy ratings.
The outlook suggests cautious optimism as Marqeta transitions to profitability amid competitive fintech pressures. Key risks include execution on new initiatives and maintaining growth momentum. Upside potential exists if recent partnerships drive sustained revenue acceleration, but high valuation multiples require continued strong performance to justify.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
